Shared genetic contribution of type 2 diabetes and cardiovascular disease: Implications for prognosis and treatment [PDF]
, 2018 Purpose of Review: The increased cardiovascular disease (CVD) risk in subjects with type 2 diabetes (T2D) is well established. This review collates the available evidence and assesses the shared genetic background between T2D and CVD: the causal ...
Strawbridge, Rona J. +1 more
core +1 more source
Recent Advances in Encapsulation, Protection, and Oral Delivery of Bioactive Proteins and Peptides using Colloidal Systems [PDF]
, 2020 There are many areas in medicine and industry where it would be advantageous to orally deliver bioactive proteins and peptides (BPPs), including ACE inhibitors, antimicrobials, antioxidants, hormones, enzymes, and vaccines. A major challenge in this area
McClements, David Julian +1 more
core +3 more sources
Design and Baseline Characteristics of Participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) Trial of Dulaglutide's Cardiovascular Effects [PDF]
, 2018 DigitalThe aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucagon-like peptide 1 analogue that lowers blood glucose, body weight, appetite and blood pressure, on cardiovascular outcomes.
Atisso, Charles M. +32 more
core +1 more source
JCI Insight, 2023 Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in the neurobiology of addictive behaviors, and GLP-1 analogues may be used for the treatment of alcohol use disorder (AUD).
Vicky Chuong +10 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Introduction: Oral semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that improves glycated hemoglobin levels and body weight in patients with type 2 diabetes (T2DM).
Zhen Feng +4 more
doaj +1 more source
A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality? [PDF]
, 2017 The EMPA-REG OUTCOME and the LEADER trials have revealed a new era in the management of type 2 diabetes. The SGLT2 inhibitor empagliflozin demonstrated a lower rate of the primary composite outcome of death from cardiovascular causes, nonfatal myocardial
Rossello, X, Yellon, DM
core +1 more source
Medicines, 2022 Background and Objectives: This study aimed to investigate the changes in obesity severity, glucose metabolism, and body composition in patients with obesity and type 2 diabetes mellitus treated with glucagon-like peptide 1 receptor agonist (GLP1-RA ...
Yoshinori Ozeki +7 more
doaj +1 more source
The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]
, 2013 Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core +2 more sources
Oral diabetes medication monotherapy and short-term mortality in individuals with type 2 diabetes and coronary artery disease [PDF]
, 2018 Objective To determine whether sulfonylurea use, compared with non-sulfonylurea oral diabetes medication use, was associated with 2-year mortality in individuals with well-controlled diabetes and coronary artery disease (CAD). Research design and methods
Berkowitz, Seth A +7 more
core +3 more sources
Journal of Comparative Effectiveness Research, 2022 What is this summary about? This is a plain language summary of the STEP TEENS research study, which was originally published in the New England Journal of Medicine.
Daniel Weghuber +5 more
doaj +1 more source